Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430455 · ClinicalTrials.gov registry record · Phase 4
Tranylcypromine Treatment of Bipolar Depression
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT01430455 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 7 participants.
The verdict
NCT01430455, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study seeks to investigate whether tranylcypromine (Parnate®) might be an effective treatment of bipolar depression. New treatments are needed, as there is little evidence that standard antidepressants are effective in treating this condition, and the two antipsychotic medications that have indications for bipolar depression can cause substantial side effects. This study will focus specifically on currently depressed outpatients having a bipolar history for whom at least one standard antidepressant medication was ineffective. Patients will be treated openly with tranylcypromine for 8-10 months, depending on treatment response.
Interventions
- DRUG Tranylcypromine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01430455
The ClinicalTrials.gov registry entry for NCT01430455 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tranylcypromine is the first listed.
NCT01430455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01430455 about?
NCT01430455 is a clinical study titled "Tranylcypromine Treatment of Bipolar Depression". This study seeks to investigate whether tranylcypromine (Parnate®) might be an effective treatment of bipolar depression. New treatments are needed, as there is little evidence that standard antidepressants are effective in treating this condition, and the two antipsychotic medications that have ind...
What is the current status of trial NCT01430455?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2011-11. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01430455?
The interventions under investigation include: Tranylcypromine (DRUG).
Who is sponsoring clinical trial NCT01430455?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.